BE-MOBILYZED: BElimumab to MOBIlise memory B-cells from secondary LYmhoid organs to improve memory B-cell HLA-specificity profiling to support delisting for transplant access in highly-sensitiZED.

Start Date01 Sep 2025

Sponsor / Collaborator-

NCT07138898

/ Not yet recruitingPhase 2IIT

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

The purpose of this study is to assess the incidence of rheumatologic flares, changes in pain scores (VAS), changes in functional outcomes (PROMIS), wound complications, surgical site infections, and return trips to the operating room for rheumatology patients following shoulder replacements, comparing those who stop their immunosuppressants preoperatively for the same amount of time as suggested in the literature for hip and knee arthroplasty versus those who hold the medications for a shorter period of time preoperatively.

Start Date01 Sep 2025

Sponsor / Collaborator

NYU Langone Health

NCT06716606

/ RecruitingPhase 3

An Open Label Study to Investigate the Long-term Safety and Efficacy of Belimumab Administered Subcutaneously in Adults With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)

This is an open label extension (OLE) study of an ongoing randomized controlled clinical study 218224 (Parent Study). The OLE study will describe how well tolerated belimumab will be long term, and whether it might continue to slow progression of lung function decline, slow overall disease progression and improve quality of life.

Start Date12 Dec 2024

Sponsor / Collaborator

GSK Plc

[+1]

100 Clinical Results associated with Belimumab

100 Translational Medicine associated with Belimumab

100 Patents (Medical) associated with Belimumab

1,288

Literatures (Medical) associated with Belimumab

01 Dec 2025·JOURNAL OF MEDICAL ECONOMICS

Comparison of utilization and total medicare fee-for-service expenditures for subcutaneous versus intravenous versions of a select group of therapies.

Article

Author: Sarocco, Phillip ; Kardel, Peter ; Maynard, Jason ; Sheetz, Caitlin

INTRODUCTION:

Comparisons of subcutaneous (SC) and intravenous (IV) delivery of biotherapeutics in Europe have revealed differences in cost, convenience, and preference. In the US, claims-based studies comparing SC and IV delivery have been limited. This study compared resource utilization and expenditures between cohorts of patients receiving the same drug by the SC or IV route of administration (ROA) across several indications.

METHODS:

Medicare Fee-For-Service claims were compared between cohorts of patients who received SC- or IV-delivered abatacept, belimumab, daratumumab, infliximab, tocilizumab, trastuzumab/pertuzumab, or vedolizumab. For each drug, utilization rates and healthcare expenditures per service site were compared between ROAs. Observed differences in baseline characteristics were accounted for using Inverse Probability Treatment Weighting models that balanced pre-index differences between ROAs per drug. Each ROA comparison per drug and service site was weighted and conducted independently.

RESULTS:

Across seven drugs, a total sample size of 158,632 (72,820 IV; 85,812 SC) was analyzed. For most comparisons, high-spend sites were utilized at a higher rate for IV administration. In particular, all comparisons revealed more frequent hospital outpatient department utilization for the IV ROA. For five of the seven drugs, SC treatment was associated with lower mean total Medicare expenditures, with savings of up to $56,000 per patient annually. Although three SC treatments had higher medication index spend, the total spend for these drugs across sites was significantly lower for SC delivery.

LIMITATIONS:

Limitations of this study include differences in billing between the SC and IV ROAs, potential treatment selection bias, and the assumption of equivalent efficacy.

CONCLUSIONS:

To our knowledge, this study was the first and largest US Medicare claims analysis, comparing patients receiving SC or IV versions of the same therapeutic across multiple drugs and indications. Findings demonstrated that SC delivery may facilitate reduced resource utilization and expenditures across drugs and disease indications.

01 Dec 2025·IMMUNOLOGIC RESEARCH

Effects of belimumab on peripheral blood Breg cells and cytokines in childhood systemic lupus erythematosus

Article

Author: Qiu, Shan ; Peng, Qianqian ; Zhang, Ruifeng ; Chen, Na ; Lu, Qian ; Yuan, Tingting ; Zhong, Zhaowen ; Lv, Juan

To evaluate the therapeutic effectiveness of belimumab (BLM) in childhood systemic lupus erythematosus (cSLE) by analyzing peripheral blood Breg cell subsets and related cytokines at multiple time points post-treatment, compared with conventional therapy. From January 2023 to August 2023, 36 cSLE patients receiving BLM plus standard therapy (BLM group) and 35 receiving standard therapy alone (conventional group) were enrolled. Thirty age- and sex-matched healthy children were included as controls. Flow cytometry was used to detect absolute counts and ratios of peripheral Breg cell subsets at baseline, 6 weeks, 6 months, and 1 year. Serum cytokine levels (IL-2, IL-10, IL-21, IL-35, and IFN-γ) were measured by ELISA. After 6 weeks, IL-2, IL-21, and IFN-γ levels decreased significantly in both groups (P > 0.05 between groups); however, after 6 months and 1 year, these cytokines remained lower in the BLM group (all P < 0.05). IL-10 and IL-35 levels increased in both groups from week 6, with a milder increase in the BLM group (all P < 0.05). CD3⁻CD19⁺ B cells declined in both groups, with significant intergroup differences (P < 0.001). The BLM group showed a higher proportion of CD27⁺CD24⁺ B cells at week 6 compared to the conventional group (P < 0.05), but this reversed at 1 year (P < 0.05). CD38⁺CD24⁺ B cells were significantly higher in the BLM group at 6 months and 1 year (P < 0.001), while the conventional group showed no significant change after 6 weeks (P > 0.05). At baseline, the relative proportion of CD38⁺CD19⁺ B cells was higher in the BLM group than in the conventional treatment group (all P < 0.05). With ongoing treatment, both groups showed a decreasing trend in B cell proportions, with statistically significant differences observed within each group (all P < 0.05). Moreover, the decline in the BLM group was more pronounced compared to the conventional group at corresponding time points (all P < 0.05). Belimumab may exert immunomodulatory effects in childhood systemic lupus erythematosus by influencing peripheral Breg cell subsets and cytokine profiles. Compared with conventional therapy, it appears to provide more sustained regulation of certain immune parameters over time. These findings suggest its potential as a complementary therapeutic option targeting B cell dysregulation in cSLE, although further studies are needed to confirm these observations and clarify the underlying mechanisms.

01 Nov 2025·Arthritis & Rheumatology

Differences in Dynamics of Specific Antinuclear Antibodies and Their Susceptibility to B Cell–Targeting Treatment in Patients With Systemic Lupus Erythematosus

Article

Author: Aranow, Cynthia ; van Kooten, Cees ; van Schaik, Mieke ; Mackay, Meggan ; Cooney, Laura ; Fox, David A. ; Suurmond, Jolien ; Teng, Y. K. Onno ; Diamond, Betty ; Smilek, Dawn ; Toes, René E. M. ; Arends, Eline J. ; Dall'Era, Maria ; van Dooren, Hugo J. ; Huizinga, Tom W. J. ; Wofsy, David ; Dorjée, Annemarie L.

Objective:

The presence of antinuclear antibodies (ANAs) is characteristic for systemic lupus erythematosus (SLE). Antibody dynamics over time are thought to reflect the cellular source of ANAs and their therapeutic targetability. Anti–double‐stranded DNA (anti‐dsDNA) is the most prevalent and well‐studied of all ANAs, and fluctuations in anti‐dsDNA serum levels are associated with disease activity. Antibody dynamics of other ANAs, such as antibodies targeting RNA‐binding proteins (RBPs), are often considered more stable compared to anti‐dsDNA. However, anti‐RBPs may be heterogeneous in nature, and their fluctuation has not been extensively analyzed. Therefore, we aimed to study the dynamics of the different ANAs and their susceptibility to B cell–targeting treatments in patients with SLE.

Methods:

Seroconversion of specific ANAs was analyzed using electronic health records from patients with SLE. Titers of specific ANAs and anti‐varicella zoster virus (VZV) were determined in serum samples from a longitudinal cohort of patients with SLE and serum from patients with SLE treated with rituximab and belimumab.

Results:

Anti‐Smith (anti‐Sm) and anti‐RNP, similar to anti‐dsDNA titers, seroconverted more frequently compared to anti–SS‐A/SS‐B. Furthermore, anti‐Sm/RNP and anti‐dsDNA titers, but not anti–SS‐A/SS‐B titers, fluctuated significantly compared to stable anti‐VZV controls. Likewise, reductions in anti‐dsDNA and anti‐Sm/RNP titers after B cell–depleting treatment were comparable in magnitude. However, only anti‐dsDNA titer reductions associated with clinical outcomes.

Conclusion:

Together, these results show that anti‐Sm/RNP and anti‐dsDNA, in contrast to anti–SS‐A/SS‐B, frequently fluctuate and their levels can decrease following B cell–targeted treatments. Thus, distinct ANAs have variable kinetics, potentially reflecting their derivation from different B cell differentiation pathways.image

105

News (Medical) associated with Belimumab

28 Oct 2025

·www.fiercepharma.com

After lupus nephritis nod, Roche keeps Gazyva momentum rolling with phase 3 win in another kidney condition

Steroids remain the cornerstone of current idiopathic nephrotic syndrome treatment, according to Roche, but the potential for serious side effects limits long-term use, and many patients experience relapses regardless. On the heels of last week’s lupus nephritis nod from the FDA, Roche’s Gazyva is proving once again that it still has new tricks despite its 12 years on the market—and not just in its original oncology field, either.Pitted against the immunosuppressant mycophenolate mofetil (MMF), Roche’s CD20-targeting antibody Gazyva (obinutuzumab) helped more kids and young adults with idiopathic nephrotic syndrome (INS) achieve sustained remission after one year, according to a top-line readout from the Swiss drugmaker’s late-stage INShore trial.Improvements associated with Gazyva in the study—which enrolled 85 people with INS between the ages of 2 and 25 years old—were statistically significant and clinically meaningful, allowing the trial to hit its primary endpoint, Roche’s Genentech unit said in an Oct. 28 press release.Roche did not disclose detailed results from the study Tuesday, noting that it will share the full readout at a future medical meeting. Emboldened by the trial, Roche said it also plans to provide the data to global regulators, including the FDA and the European Medicines Agency. Gazyva was originally green lit in 2013 to treat chronic lymphocytic leukemia, and, up until last week, the drug’s four approved indications were all in the field of oncology.Oct. 20, however, Gazyva won FDA approval to treat adults with active lupus nephritis who are taking standard therapy. Like INS, lupus nephritis, which can develop from the most common form of the disease, systemic lupus erythematosus (SLE), is an immune-mediated condition that predominantly affects the kidneys.Roche figures that Gazyva, by targeting the CD20 protein, could tackle a range of immune-mediated kidney and kidney-related conditions driven by disease-causing B cells.In the case of INS, the autoimmune disease—typically diagnosed during early childhood—is defined by “unpredictable” relapses that lead to fatigue, swelling, weight gain and greater vulnerability to infections and clotting, Roche explained. The condition may also cause anxiety and depression triggered by “fear of relapse and social isolation,” the company added.Steroids remain the cornerstone of current INS treatment, according to Roche, but the potential for serious side effects limits long-term use, and many patients still experience relapses under this approach.In the INShore trial, Roche defined complete INS remission as the absence of relapses during the study period, alongside a low amount of protein in the urine at the 52-week mark.Gazyva also succeeded across a series of key secondary endpoints, charting improvements over MMF in relapse-free survival, median time to relapse or death, reduction in cumulative corticosteroid dosing from baseline to a year and fewer relapses from baseline to Week 52, Roche said.On certain other endpoints, however, Gazyva “showed no significant difference” in performance over MMF, Roche admitted. The endpoints where Gazyva showed parity with the immunosuppressant MMF included sustained complete remission, probability of relapse-free survival, the proportion of patients who experienced edema-associated relapse and mean change on a measure of “general fatigue,” among others.No new safety signals cropped up in the study, and Gazyva’s overall safety profile was on par with results from previous studies of the drug in adults, Roche pointed out.“These results show that Gazyva may achieve robust disease control with a reduced need for corticosteroids, which are associated with serious side effects over time,” Levi Garraway, M.D., Ph.D., chief medical officer and head of global product development at Roche, said in a statement.“Idiopathic nephrotic syndrome is a severe and chronic kidney disease usually diagnosed in early childhood, yet meaningful treatment progress has been limited,” he continued. “As a targeted therapy, Gazyva has the potential to help address this unmet need and we look forward to sharing the data with health authorities.” While the INS market remains generally untapped by novel branded drugs, Gazyva will face greater competition in its new lupus nephritis indication, where GSK’s Benlysta is dominant and AstraZeneca’s Saphnelo first graced the stage in 2021. Aside from lupus nephritis and INS, Roche is also testing Gazyva in membranous nephropathy, rare immune-mediated kidney diseases and SLE.In 2024, while still operating exclusively in the realm of blood cancers, Roche’s antibody drug secured (PDF) full-year sales of 910 million Swiss francs (roughly $1.15 billion), growing 16% over 2023.

Clinical ResultDrug ApprovalPhase 3ADC

28 Oct 2025

·www.biospace.com

Biogen Seeks to Stand Out in Lupus With New Anti-CD40L Data

iStock, Veronique D Phase III data for dapirolizumab pegol presented at the 2025 conference of the American College of Rheumatology showed quality-of-life benefits in systemic lupus erythematosus that could see Biogen go head-to-head with GSK and AstraZeneca in a blockbuster space. Biogen’s CD40L inhibitor dapirolizumab pegol significantly improved quality of life in a late-stage study of patients with systemic lupus erythematosus, potentially giving the molecule an edge in a competitive field. Jefferies analysts, writing in a note to investors Monday, said Biogen and development partner UCB have already shown dapirolizumab pegol to be a “competitive” therapy for systemic lupus erythematosus (SLE) in previous readouts that were based on “traditional efficacy measures” such as treatment response and disease activity. These additional findings, to be presented Tuesday at the 2025 conference of the American College of Rheumatology, point to “added benefits” across a variety of clinical and patient-reported measures that, according to the analysts, could make a strong market case for dapirolizumab pegol. Additionally, the analysts noted that these quality-of-life advantages could underlie the asset’s “potential to differentiate in SLE.” The group currently models more than $1 billion in peak sales for dapirolizumab pegol. Tuesday’s data come from the Phase III PHOENYCS GO trial, which enrolled more than 300 patients with moderate to severe active SLE. Dapirolizumab pegol was dosed every four weeks on top of standard of care. Patients on the dapirolizumab pegol regimen had greater improvements in fatigue, pain and body image versus placebo comparators. Similarly, Biogen’s therapy resulted in better physical and emotional health outcomes, alongside stronger improvements in the intimate relationships, planning and burden to others domains, as compared with placebo. These findings follow a previous readout from PHOENYCS GO, presented in November 2024, in which dapirolizumab pegol outperformed placebo in terms of clinical outcomes. At the time, data revealed that the CD40L blocker hit a response rate of 49.5%, versus 34.6% in placebo comparators. Dapirolizumab pegol also demonstrated a 1.8-fold greater improvement in a disease activity measure compared with controls. With dapirolizumab pegol, Biogen and UCB are building up to compete with AstraZeneca’s Saphnelo and GSK’s Benlysta, which according to Jefferies have a “combined $3B run rate.” In 2024, Saphnelo surged 70% to make $474 million worldwide, while Benlysta brought in almost $2 billion, representing 14% annual growth. To further boost dapirolizumab pegol’s case, Biogen is also running the Phase III PHOENYCS FLY study , likewise in patients with moderate to severe SLE. The trial is currently recruiting participants, with a primary completion date of May 2028. “We think [dapirolizumab pegol] represents one of BIIB’s several late-stage, $1B+ blockbuster pipeline programs that could garner more credit in 2026, ahead of [its] second Phase III readout in 2027-28,” Jefferies wrote.

Phase 3Clinical Result

28 Oct 2025

·www.bioheng.com

ACR 2025 | Bioheng Therapeutics Presents Latest Clinical Data on Allogeneic CAR-T Therapy CTA311 and CTA313 for Patients with Autoimmune Diseases

From October 24 to 29, 2025, the American College of Rheumatology (ACR) Convergence 2025 was grandly held in Chicago, USA. At this event, Bioheng Therapeutics presented the latest clinical results of CTA311, its allogeneic anti-CD19 CAR-T product for systemic lupus erythematosus (SLE) and ANCA-associated vasculitis (AAV), and CTA313, its allogeneic anti-CD19/BCMA CAR-T product for SLE and lupus nephritis (LN), in the form of academic posters. Abstract Title: Preliminary Safety, Efficacy, and Cellular Kinetics of CTA311, a CD19 Targeted Universal CAR-T Therapy, for Active Autoimmune Diseases Abstract Code: 2129320 Poster Code: 2452 Session: Systemic Lupus Erythematosus – Treatment Poster III Presentation Time: Tuesday, October 28, 10:30 AM - 12:30 PM CT The poster at ACR Convergence 2025 detailed the results of an investigator-initiated trial. This single-arm, open-label, dose-escalation study evaluated the safety and efficacy of CTA311 in patients with SLE and AAV. Four dose levels were explored (DL1: 0.2×106 CAR+ T cells/kg; DL2: 1.0×106 CAR+ T cells/kg; DL3: 3.0×106 CAR+ T cells/kg; DL4: 6.0×106 CAR+ T cells/kg). All patients received lymphodepletion with fludarabine (30 mg/m2/day × 3 days) and cyclophosphamide (300 mg/m2/day × 3 days) prior to CTA311 infusion. As of August 30, 2025, a total of 11 patients were enrolled, including 10 with SLE and 1 with AAV.Ten patients (91%) were female, with a median age of 31 years (range: 21-55), and 64% patients previously received biologics including belimumab and telitacicept. Safety: CTA311 was well tolerated with no dose-limiting toxicities (DLT), neurotoxicity or graft-versus-host disease (GvHD) events reported. Cytokine release syndrome (CRS) events occurred in 82% (n=9), all low grade (G) (7 G1 and 2 G2). Three patients experienced treatment related infections (1 pneumonia (G3) and CMV reactivation (G1), 1 fungal infection (G2), and 1 infection NOS (G1)), which all fully resolved with antimicrobial treatment. Efficacy and Cellular Kinetics: In SLE/LN, preliminary analysis indicates elimination of autoantibodies, improvement in C3 levels, and decline in proteinuria leading to improvement in disease activity scores SLEDAI-2K and PGA. Responses were dose dependent with 100% LLDAS and 50% DORIS at DL4. In AAV, the patient achieved a BVAS score of 0 at M3 and M4 from baseline 8. A minor symptom (arthritis) reappeared at M6 but resolved at M9 without any adjustment in medication. PK analysis revealed peak expansion of CAR-T cells approximately 7-21 days post-infusion, with a dose-dependent pattern, suggesting the potential for deeper remission at higher dose levels. Pharmacodynamics: Complete B cell depletion was observed by Day 4 post-infusion with recovery starting Day 42. In patients that achieved anti-dsDNA antibodies eradication, the anti-dsDNA antibodies remained undetected up to 12 months, and ongoing, despite B-cell recovery. CTA311 exhibited an acceptable safety profile in patients with SLE, LN and AAV, and displayed robust expansion coincided with profound B-cell depletion and concomitant elimination of pathogenic autoantibodies, leading to marked clinical improvement in these patients. Future clinical studies are warranted to further evaluate and characterize the efficacy and safety of CTA311 in patients with SLE or other B cell-driven autoimmune diseases. Abstract Title: Preliminary Safety, Efficacy, and Cellular Kinetics of CTA313, a CD19/BCMA Dual-Targeted Universal CAR-T Therapy, for Active Systemic Lupus Erythematosus Abstract Code: 2129706 Poster Code: 1532 Session: Systemic Lupus Erythematosus – Treatment Poster II Presentation Time: Monday, October 27, 10:30 AM - 12:30 PM CT The poster at ACR Convergence 2025 detailed the results of an investigator-initiated trial. This single-arm, open-label, dose-escalation study evaluated the safety and efficacy of CTA313 in patients with SLE/LN. Three dose levels were explored (DL1: 3×106 CAR+ T cells/kg; DL2: 6×106 CAR+ T cells/kg; DL3: 10×106 CAR+ T cells/kg). All patients received lymphodepletion with fludarabine (30 mg/m2/day × 3 days) and cyclophosphamide (300 mg/m2/day × 3 days) prior to CTA313 infusion. As of September 20, 2025, a total of 15 patients were enrolled, including 6 (40%) with SLE and 9 (60%) with LN, with a median age of 37 years (range: 21-50). In terms of safety, no immune effector cell-associated neurotoxicity syndrome (ICANS) or graft-versus-host disease (GvHD) was observed at any dose level. Only Grade 1 Cytokine release syndrome (CRS) was observed in 6 patients (40%), largely self-limiting. All Grade 3 infections fully resolved with antimicrobial treatment. Regarding efficacy, with a median follow-up of 4 months, 100% of patients achieved the Systemic Lupus Erythematosus Responder Index-4 (SRI-4), 79% achieved Lupus Low Disease Activity State (LLDAS), and 43% achieved Definitions of Remission in SLE (DORIS). Robust in vivo expansion of CAR-T cells was observed, with 28-day persistence in 67% of patients. A single infusion of CAR-T cells induced complete B-cell depletion, sustained undectable anti-dsDNA antibodies, and notable reductions in other autoantibodies, including anti-Sm, anti-histone, and anti-nucleosome antibodies. Preliminary results indicate that CTA313 can rapidly and durably control disease activity in patients with SLE and LN, with an acceptable safety profile. Ongoing clinical studies are further evaluating CTA313 in patients with other B cell-driven autoimmune diseases. About CTA311 and CTA313 Both CTA311 and CTA313 are allogeneic CAR-T products derived from healthy donors. CTA311 targets CD19, whereas CTA313 targets both CD19 and BCMA. Both products are developed based on Bioheng Therapeutics’ proprietary allogeneic CAR-T platform—ANSWER®—which incorporates genetic modifications to prevent graft-versus-host disease (GvHD) and host-versus-graft rejection (HvG). These products can be manufactured in advance and stored for multiple patients, providing an "off-the-shelf" solution for patients in need of CAR-T cell therapy. Leveraging the ANSWER® platform, Bioheng Therapeutics is actively developing a broad pipeline of allogeneic CAR-T programs. These programs have demonstrated robust and durable persistence of allogeneic CAR-T cells, highlighting strong therapeutic potential in both autoimmune diseases and oncology.

Clinical ResultImmunotherapyCell TherapyAACRClinical Study

100 Deals associated with Belimumab

External Link

KEGG	Wiki	ATC	Drug Bank
D03068	Belimumab	L04AA26	DB08879

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Lupus Nephritis	European Union	GlaxoSmithKline Trading Services Ltd.	13 Jul 2011
Lupus Nephritis	Iceland	GlaxoSmithKline Trading Services Ltd.	13 Jul 2011
Lupus Nephritis	Liechtenstein	GlaxoSmithKline Trading Services Ltd.	13 Jul 2011
Lupus Nephritis	Norway	GlaxoSmithKline Trading Services Ltd.	13 Jul 2011
Systemic Lupus Erythematosus	United States	GlaxoSmithKline LLC	09 Mar 2011

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bronchial Diseases	Phase 3	China	GSK Plc	12 Dec 2024
Bronchial Diseases	Phase 3	Japan	GSK Plc	12 Dec 2024
Bronchial Diseases	Phase 3	Argentina	GSK Plc	12 Dec 2024
Bronchial Diseases	Phase 3	South Korea	GSK Plc	12 Dec 2024
Connective Tissue Diseases	Phase 3	United States	GSK Plc	11 Sep 2024
Connective Tissue Diseases	Phase 3	China	GSK Plc	11 Sep 2024
Connective Tissue Diseases	Phase 3	Japan	GSK Plc	11 Sep 2024
Connective Tissue Diseases	Phase 3	Argentina	GSK Plc	11 Sep 2024
Connective Tissue Diseases	Phase 3	Australia	GSK Plc	11 Sep 2024
Connective Tissue Diseases	Phase 3	Belgium	GSK Plc	11 Sep 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05917288 (CTgov)	Phase 1	Systemic Lupus Erythematosus	16	Belimumab (Belimumab 200 mg/mL Every Week)	gbidhnyvcu(dwbqdmmqws) = xajlwemivl nyqaeovhgg (weafoafuan, 27.50) View more	-	14 Nov 2025
				Belimumab (Belimumab 200 mg/mL Every 10 Days)	nswazfipng(hqsxwmhsgl) = tzrlumvfow nvslhkwseo (kvuhlsbaex, 17.44) View more
NCT04515719 (Ann Rheum Dis) Manual	Phase 4	Systemic Lupus Erythematosus	231	BelimumabBelimumab 120 mg + SOC	tnykipsoaf(kwdqogknsn) = jkduajcsod xibxqyaggu (glgvsguwcp ) Met View more	Positive	06 Nov 2025
				Placebo (saline) + SOC	tnykipsoaf(kwdqogknsn) = fkqzvqzwqf xibxqyaggu (glgvsguwcp ) Met View more
NCT04515719 (Pubmed \| Ann Rheum Dis)	Phase 4	Systemic Lupus Erythematosus	231	Low-dose belimumab	nlnhnknbub(xbtqtaechc) = whnyvxyemb ccuzxulvth (oxcnooegfo ) View more	Positive	01 Nov 2025
				Placebo (saline)	nlnhnknbub(xbtqtaechc) = xqhycutixo ccuzxulvth (oxcnooegfo ) View more
NCT04515719 (ACR2025) Manual	Phase 4	Systemic Lupus Erythematosus	231	BelimumabBelimumab 120mg + Standard of Care	jsejmmauyl(nosimrfxgk) = qjonzkjqsp oildzdjuoe (focccyftkn ) Met View more	Positive	24 Oct 2025
				Placebo + Standard of Care	jsejmmauyl(nosimrfxgk) = qybpuijnje oildzdjuoe (focccyftkn ) Met View more
NCT00410384 (ACR2025)	Phase 3	Systemic Lupus Erythematosus	2,386	Belimumab	wtyswazmvp(pduqjgnxhf) = tpdldcqxns oajhhamjsq (tgkvmzcita ) View more	Positive	24 Oct 2025
				Placebo	hjafruberh(creddeflxl) = tjdgmnbkvu ivdlhyxsqe (jwnbhobvdh ) View more
NCT00424476 (BLISS-52, ACR2025)	Phase 3	Systemic Lupus Erythematosus	910	Belimumab+Antimalarials+Glucocorticoids	tnqqkkzlqh(syvcvojvdg) = uexwsgihvk lcwowxbkqp (kkvdtrakea ) View more	Positive	24 Oct 2025
				Immunosuppressants+Antimalarials+Glucocorticoids	tnqqkkzlqh(syvcvojvdg) = lmejcouoxv lcwowxbkqp (kkvdtrakea ) View more
RELIABLE (ACR2025)	Not Applicable	Systemic Lupus Erythematosus	400	Belimumab	vexeshihny(sfpepaqswl) = qiynlngbdl stuejwkvsm (nrqzqavixi ) View more	Positive	24 Oct 2025
JULES (ACR2025)	Not Applicable	Systemic Lupus Erythematosus	67	Belimumab	sinlamtgmw(qdmpmdhykg) = hueiokqgaa ypappkuhuf (vpfmjzdsph ) View more	Positive	24 Oct 2025
ACR2025	Not Applicable	Systemic Lupus Erythematosus anti-SSA \| anti-SSB \| anti-Jo-1 ... View more	125,675	Belimumab	bhvgtwezqb(fzzqivjahx) = nvjsbudkre uklxwrhmqy (dlagypgnll ) View more	Negative	24 Oct 2025
				Anifrolumab	yjgsevvytj(hobucyqccg) = kyhexdlriq gltrcidpxi (otanskokvs ) View more
NCT01639339 (BLISS-LN, ACR2025)	Phase 3	Lupus Nephritis	271	Belimumab	fspdyarbro(yvkjmkkvck) = yamfuvjrvo vcwltvxalr (qvoxxduzvq )	Positive	24 Oct 2025
				Placebo	fspdyarbro(yvkjmkkvck) = naswwvjupg vcwltvxalr (qvoxxduzvq )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis